VERAXA Biotech AG (NASDAQ: VRXA) announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
According to VERAXA, integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
The BiTAC platform is a proprietary technology that enables the creation of bispecific T-cell engagers, which are designed to recruit the patient's own immune system to attack cancer cells. By leveraging Ardigen's AI capabilities, VERAXA aims to more efficiently identify optimal target pairs that could lead to more effective and safer therapies. This approach is particularly relevant for addressing the challenges of on-target, off-tumor toxicity that has hindered many immunotherapies.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats. Guided by quality-by-design principles, VERAXA is advancing its pipeline into clinical development.
The collaboration with Ardigen marks a strategic move to incorporate computational biology into VERAXA's drug discovery process. By analyzing vast datasets, AI can help predict which drug combinations will be most effective and least toxic, potentially accelerating the development of new treatments. This partnership underscores the growing trend of integrating AI into oncology research to improve success rates and bring precision medicine to patients more quickly.
For more information on VERAXA Biotech AG and its latest news, visit the company's newsroom at http://ibn.fm/VRXA. The full press release about this partnership is available at https://ibn.fm/GLFg2.
